Lavie Bio Secures Canadian Regulatory Approval For Thrivus
Portfolio Pulse from Benzinga Newsdesk
Lavie Bio has secured Canadian regulatory approval for Thrivus, a bio-inoculant seed treatment that increases Hard Red Spring Wheat production by improving soil nutrient availability and efficiency, mitigating environmental stresses, and enhancing production in sub-optimal areas.
May 24, 2023 | 11:16 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lavie Bio, a subsidiary of Evogene, has received Canadian regulatory approval for Thrivus, a bio-inoculant seed treatment that could increase Hard Red Spring Wheat production.
Lavie Bio is a subsidiary of Evogene (EVGN). The Canadian regulatory approval for Thrivus is a positive development for the company, as it allows them to expand their market and potentially increase revenues. This news is likely to have a positive short-term impact on Evogene's stock price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100